Drug intelligence / Profile preview

ASX-100

Development stage: Preclinical
Lead developer: Asalyxa Bio
Modality: Non-biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems

Overview

**ASX-100** is the lead candidate from Asalyxa Bio, a University of Michigan spinout company, featuring a novel neutrophil-targeting drug delivery platform. It is a spherical polymer particle designed to deliver anti-inflammatory effects directly to overreactive neutrophils, degrading into salicylic acid—an active metabolite of aspirin—and a safe food additive. The technology addresses excessive neutrophil activity implicated in acute respiratory distress syndrome (ARDS) and severe inflammatory conditions like COVID-19, aiming to reduce inflammation with high specificity and minimal systemic side effects.[4][5][8]

Beyond the preview

Go deeper on ASX-100.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ASX-100.

Explore the full profile